Ligand Pharmaceuticals, Inc. (LGND) Tops Q2 EPS by 10c; Boosts FY14 Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Ligand Pharmaceuticals, Inc. (LGND) Tops Q2 EPS by 10c; Boosts FY14 Outlook

Roth Still Positive on Ligand (LGND) Following Q2 Results, ASPIRE Phase 3 Update (AMGN)

August 4, 2014 2:24 PM EDT

Roth Capital affirms Ligand Pharma (Nasdaq: LGND) with a Buy rating and $92 price target following Q2 results and update issued earlier Monday.

Analyst Joseph Pantginis commented We believe LGND is in its strongest financial position to date with a growing cash balance, debt fully... More